Abonnement à la biblothèque: Guest
Portail numérique Bibliothèque numérique eBooks Revues Références et comptes rendus Collections
International Journal of Medicinal Mushrooms
Facteur d'impact: 1.423 Facteur d'impact sur 5 ans: 1.525 SJR: 0.433 SNIP: 0.661 CiteScore™: 1.38

ISSN Imprimer: 1521-9437
ISSN En ligne: 1940-4344

Volumes:
Volume 21, 2019 Volume 20, 2018 Volume 19, 2017 Volume 18, 2016 Volume 17, 2015 Volume 16, 2014 Volume 15, 2013 Volume 14, 2012 Volume 13, 2011 Volume 12, 2010 Volume 11, 2009 Volume 10, 2008 Volume 9, 2007 Volume 8, 2006 Volume 7, 2005 Volume 6, 2004 Volume 5, 2003 Volume 4, 2002 Volume 3, 2001 Volume 2, 2000 Volume 1, 1999

International Journal of Medicinal Mushrooms

DOI: 10.1615/IntJMedMushr.v11.i2.60
pages 167-184

Preclinical Evaluation of Concurrent Medicinal Mushroom-Based Immune-Enhancement Supplementation in Dogs Undergoing Chemotherapy for Various Cancers

Britt M. Gianotti
Aloha Medicinals Inc., Carson City, NV 89706, USA
Matt P. Cleaver
Aloha Medicinals Inc., Carson City, NV 89706, USA
Marie N. Mullins
Animal Hospital Specialty Center, Highlands Ranch, CO 80126; Veterinary Cancer Care of Santa Fe, NM, USA
Sharon Y. West
Veterinary Cancer Care of Santa Fe, NM, USA

RÉSUMÉ

Chemotherapy is one of the most common treatments for canine cancer, although it is frequently quite toxic and can result in disruptions of the dog's normal biochemical and physiological cycles. Chemotherapy is known to often drive the dog's white blood cell count down (neutropenia), causing the immune system to weaken and raising susceptibility to opportunistic infections. This often causes chemotherapy schedules to be interrupted, resulting in less-efficacious treatment. Neutropenic patients are commonly symptomatic, exhibiting such side effects as anorexia, diarrhea, vomiting, fever, and death. Historically, neutropenia is one of the main factors considered in directing chemotherapy cycles. This study was conducted to determine the effectiveness of a popular mushroom-based veterinary immune-enhancement supplement, K-9 ImmunityTM, and its adjunct K-9 Transfer FactorTM, when used concurrently with chemotherapy. The objectives of this study were several: to determine if immune supplementation could reduce neutropenia when partnered with chemotherapy, to determine if the incidence of side effects would be reduced, and to determine the overall effect on quality of life in the face of the chemotherapy. In addition to their regularly prescribed cancer treatments and medicines, dogs in this study received a daily dose of nonspecific immune-enhancement supplements: one 500 mg capsule per 4.5 kg body weight per day of K-9 ImmunityTM and one 3000 mg wafer per day (for dogs greater than 11 kg) or 1/2 wafer per day (for dogs under 11 kg) of K-9 Transfer FactorTM. Four different cancer types were tracked and evaluated in this study: lymphosarcoma (LSA) (N = 21), osteosarcoma (OSA) (N = 20), mast cell tumor (MCT) (N = 19), and hemangiosarcoma (HSA) (N = 4). Various chemotherapy or palliative therapy protocols were used according to tumor type and patient suitability. Standard chemotherapy protocols were followed throughout the study, so long as biological parameters were found to be within the normal ranges. Blood parameters monitored included CBC, chemistry panel, and urinalysis, as well as radiographs and other tests per individual protocol. All patients remained in their homes with clients who were asked to make daily assessments of appetite, attitude, vomiting, diarrhea, diet, medications, and other supplements, by way of a questionnaire. Patients were brought to the clinic routinely for assessment by the veterinary staff and received treatment as prescribed. The results of this study indicate that as an adjunct to chemotherapy, these supplements do reduce the common side effects for dogs who become neutropenic. The study also showed that this type of immune-modulation therapy relieves many of the symptoms usually associated with chemotherapy and allowed the dogs to maintain a quality of life more closely related to their norm. These results indicate that further research into nonspecific immune-modulation therapy as an adjunct to chemotherapy is warranted, with the goal of improving the quality of care and quality of life that we can deliver to our canine cancer patients.


Articles with similar content:

Effect of Immunomodulating and Antiviral Agent of Medicinal Mushrooms (Immune Assist 24/7TM) on CD4+ T-Lymphocyte Counts of HIV-Infected Patients
International Journal of Medicinal Mushrooms, Vol.13, 2011, issue 2
Braimah Saaka, Abraham Quarcoo, Gideon Adotey, John Holliday, Solomon Fofie
Medicinal Value of Turkey Tail Fungus Trametes versicolor (L.:Fr.) Pilát (Aphyllophoromycetideae). A Literature Review
International Journal of Medicinal Mushrooms, Vol.6, 2004, issue 3
Christopher Hobbs
Conservative Treatment and Rehabilitation of Tennis Elbow: A Review Article
Critical Reviews™ in Physical and Rehabilitation Medicine, Vol.12, 2000, issue 3
Tuomo Pienimaki
A Randomized, Placebo-Controlled, Multicenter Study of Ganoderma lucidum (W.Curt.:Fr.) Lloyd (Aphyllophoromycetideae) Polysaccharides (Ganopoly®) in Patients with Advanced Lung Cancer
International Journal of Medicinal Mushrooms, Vol.5, 2003, issue 4
Guoliang Chen, Jingxian Ye, Yihuai Gao, Shufeng Zhou, Xihu Dai
Radiographic Evaluation of Bone-Level Implants with Wound Dehiscence between the First- and Second-Stage Surgeries
Journal of Long-Term Effects of Medical Implants, Vol.26, 2016, issue 3
Mohsen Bidgoli, Javad Faradmal, Sara Soheilifar, Erfan Abbasi Atibeh